Lineage Cell Therapeutics Stock Buy Hold or Sell Recommendation
| LCTX Stock | USD 0.61 0 0.23% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Lineage Cell Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Lineage Cell Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Lineage Cell Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Lineage Cell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Lineage and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Lineage |
Execute Lineage Cell Buy or Sell Advice
The Lineage recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lineage Cell Therapeutics. Macroaxis does not own or have any residual interests in Lineage Cell Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lineage Cell's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Lineage Cell Trading Alerts and Improvement Suggestions
| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| Lineage Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 13.97 M. | |
| Lineage Cell Therapeutics currently holds about 66.36 M in cash with (28.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Lineage Cell has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com |
Lineage Cell Returns Distribution Density
The distribution of Lineage Cell's historical returns is an attempt to chart the uncertainty of Lineage Cell's future price movements. The chart of the probability distribution of Lineage Cell daily returns describes the distribution of returns around its average expected value. We use Lineage Cell Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lineage Cell returns is essential to provide solid investment advice for Lineage Cell.
| Mean Return | -0.41 | Value At Risk | -6.56 | Potential Upside | 8.33 | Standard Deviation | 5.82 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lineage Cell historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lineage Cell Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (14.3M) | 23.1M | 23.1M | (44.3M) | 24.1M | 25.3M | |
| Free Cash Flow | (32.4M) | (19.8M) | (23.9M) | 646K | (29.2M) | (27.8M) | |
| Capital Expenditures | 440K | 64K | 354K | 413K | 674K | 680.6K | |
| Net Income | (11.8M) | (20.7M) | (43.3M) | (26.4M) | (21.5M) | (20.4M) | |
| End Period Cash Flow | 10.1M | 33.2M | 56.3M | 11.9M | 36.0M | 37.8M | |
| Change To Inventory | 122K | 2.9M | (308K) | (72K) | (82.8K) | (78.7K) | |
| Other Non Cash Items | (17.3M) | (3.5M) | 202K | 3.7M | 195K | 204.8K | |
| Depreciation | 3M | 2.0M | 873K | 727K | 692K | 657.4K | |
| Change Receivables | 1.1M | (714K) | (857K) | 50.3M | 57.9M | 60.8M | |
| Change To Netincome | (4.5M) | (3.5M) | 3.0M | 4.2M | 4.8M | 5.1M | |
| Net Borrowings | (70K) | 24.6M | (20K) | (32K) | (36.8K) | (35.0K) | |
| Investments | 17.0M | 13.0M | 9.7M | (45.7M) | 46.4M | 48.8M | |
| Dividends Paid | 40K | 25.1M | 7.2M | 37K | 33.3K | 31.6K |
Lineage Cell Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lineage Cell or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lineage Cell's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lineage stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.59 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 5.88 | |
Ir | Information ratio | -0.09 |
Lineage Cell Volatility Alert
Lineage Cell Therapeutics exhibits very low volatility with skewness of -1.71 and kurtosis of 8.9. Lineage Cell Therapeutics is a potential penny stock. Although Lineage Cell may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Lineage Cell Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Lineage instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Lineage Cell Fundamentals Vs Peers
Comparing Lineage Cell's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lineage Cell's direct or indirect competition across all of the common fundamentals between Lineage Cell and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lineage Cell or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lineage Cell's fundamental indicators could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lineage Cell to competition |
| Fundamentals | Lineage Cell | Peer Average |
| Return On Equity | -0.35 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Operating Margin | (4.17) % | (5.51) % |
| Current Valuation | 102.13 M | 16.62 B |
| Shares Outstanding | 220.42 M | 571.82 M |
| Shares Owned By Insiders | 0.44 % | 10.09 % |
| Shares Owned By Institutions | 50.56 % | 39.21 % |
| Number Of Shares Shorted | 15.94 M | 4.71 M |
| Price To Earning | 3.62 X | 28.72 X |
| Price To Book | 2.00 X | 9.51 X |
| Price To Sales | 21.64 X | 11.42 X |
| Revenue | 8.95 M | 9.43 B |
| Gross Profit | 13.97 M | 27.38 B |
| EBITDA | (24.04 M) | 3.9 B |
| Net Income | (21.49 M) | 570.98 M |
| Cash And Equivalents | 66.36 M | 2.7 B |
| Cash Per Share | 0.39 X | 5.01 X |
| Total Debt | 2.95 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 3.01 X | 2.16 X |
| Book Value Per Share | 0.36 X | 1.93 K |
| Cash Flow From Operations | (28.57 M) | 971.22 M |
| Short Ratio | 35.21 X | 4.00 X |
| Earnings Per Share | (0.10) X | 3.12 X |
| Target Price | 4.83 | |
| Number Of Employees | 68 | 18.84 K |
| Beta | 1.28 | -0.15 |
| Market Capitalization | 133.88 M | 19.03 B |
| Total Asset | 101.02 M | 29.47 B |
| Retained Earnings | (384.86 M) | 9.33 B |
| Working Capital | 20.48 M | 1.48 B |
| Current Asset | 12.84 M | 9.34 B |
| Current Liabilities | 2.74 M | 7.9 B |
Note: Acquisition by Samuel George A. Iii of 15000 shares of Lineage Cell at 0.6 subject to Rule 16b-3 [view details]
Lineage Cell Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lineage . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Lineage Cell Buy or Sell Advice
When is the right time to buy or sell Lineage Cell Therapeutics? Buying financial instruments such as Lineage Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lineage Cell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Furniture Thematic Idea Now
Furniture
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.